Published in Endocrinology on August 28, 2003
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 8.70
Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg (2006) 4.30
The role of gut hormones in glucose homeostasis. J Clin Invest (2007) 3.36
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov (2009) 3.26
Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail (2008) 2.93
The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev (2008) 2.73
Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther (2006) 2.71
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol (2012) 2.59
Insulin resistance alters islet morphology in nondiabetic humans. Diabetes (2013) 2.01
GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes (2009) 1.69
Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology (2003) 1.60
Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord (2008) 1.60
Gut feelings about diabetes. Endocrinol Nutr (2012) 1.46
Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab (2008) 1.45
Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab (2009) 1.38
Do we really know why diabetes remits after gastric bypass surgery? Endocrine (2011) 1.32
Foxa1 and Foxa2 control the differentiation of goblet and enteroendocrine L- and D-cells in mice. Gastroenterology (2009) 1.28
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag (2008) 1.27
Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol Cell Biol (2007) 1.24
Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2012) 1.20
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Rev Diabet Stud (2008) 1.19
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord (2010) 1.14
Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes (2011) 1.12
Incretin effects on β-cell function, replication, and mass: the human perspective. Diabetes Care (2011) 1.08
A model of GLP-1 action on insulin secretion in nondiabetic subjects. Am J Physiol Endocrinol Metab (2010) 1.07
Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets. Diabetologia (2011) 1.05
New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells. Horm Metab Res (2005) 1.04
Redifferentiation of expanded human pancreatic β-cell-derived cells by inhibition of the NOTCH pathway. J Biol Chem (2012) 1.04
Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochem Med (Zagreb) (2013) 1.01
Coming full circle in diabetes mellitus: from complications to initiation. Nat Rev Endocrinol (2013) 1.01
Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One (2012) 1.01
Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor. Exp Diabetes Res (2012) 0.99
Effect of gastric bypass surgery on the incretins. Diabetes Metab (2009) 0.96
Diabetes remission after bariatric surgery: is it just the incretins? Int J Obes (Lond) (2011) 0.96
Role of Gut-Related Peptides and Other Hormones in the Amelioration of Type 2 Diabetes after Roux-en-Y Gastric Bypass Surgery. ISRN Endocrinol (2012) 0.94
Epigallocatechin gallate delays the onset of type 1 diabetes in spontaneous non-obese diabetic mice. Br J Nutr (2010) 0.94
Development and functional characterization of insulin-releasing human pancreatic beta cell lines produced by electrofusion. J Biol Chem (2011) 0.93
Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance. PLoS One (2012) 0.93
β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World J Diabetes (2015) 0.92
Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month duration. Diabetes Metab J (2011) 0.91
GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud (2011) 0.91
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J Gen Med (2013) 0.91
Epac2-dependent rap1 activation and the control of islet insulin secretion by glucagon-like peptide-1. Vitam Horm (2010) 0.91
Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced β-cell damage and pancreatic Glp-1 gene therapy. Dis Model Mech (2013) 0.91
Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients. J Clin Endocrinol Metab (2008) 0.90
An odyssey of islet transplantation for therapy of type 1 diabetes. World J Surg (2007) 0.90
Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery. Mol Endocrinol (2013) 0.89
Abnormal glucose tolerance testing following gastric bypass demonstrates reactive hypoglycemia. Surg Endosc (2010) 0.89
Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience. Diabetes Metab Syndr Obes (2013) 0.89
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Ther (2015) 0.88
Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. Br J Pharmacol (2014) 0.88
Guards and culprits in the endoplasmic reticulum: glucolipotoxicity and β-cell failure in type II diabetes. Exp Diabetes Res (2011) 0.87
Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass. Osteoporos Int (2013) 0.87
Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. Diabetes (2008) 0.86
A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus. Mayo Clin Proc (2010) 0.86
New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev Diabet Stud (2005) 0.86
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists. Rev Diabet Stud (2009) 0.85
Recovery of endocrine function after islet and pancreas transplantation. Curr Diab Rep (2012) 0.85
Efficient GLP-1 gene delivery using two-step transcription amplification plasmid system with a secretion signal peptide and arginine-grafted bioreducible polymer. J Control Release (2011) 0.85
Treatment of diabetic rats with encapsulated islets. J Cell Mol Med (2008) 0.84
Management of postgastric bypass noninsulinoma pancreatogenous hypoglycemia. Surg Endosc (2010) 0.84
Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care (2013) 0.83
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag (2009) 0.83
Therapeutic Strategies to Increase Human β-Cell Growth and Proliferation by Regulating mTOR and GSK-3/β-Catenin Pathways. Open Endocrinol J (2010) 0.83
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. Diabetes Metab Syndr Obes (2010) 0.83
The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol (2010) 0.82
Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective. J Nutr Metab (2012) 0.81
Evaluation of the INS-1 832/13 cell line as a beta-cell based screening system to assess pollutant effects on beta-cell function. PLoS One (2013) 0.81
Incretin-based therapy and the quest for sustained improvements in β-cell health. Diabetes Care (2011) 0.81
A simple matter of life and death-the trials of postnatal Beta-cell mass regulation. Int J Endocrinol (2012) 0.81
GLP-1: target for a new class of antidiabetic agents? J R Soc Med (2004) 0.81
Ingestion of coffee polyphenols increases postprandial release of the active glucagon-like peptide-1 (GLP-1(7-36)) amide in C57BL/6J mice. J Nutr Sci (2015) 0.80
Serum levels of pancreatic stone protein (PSP)/reg1A as an indicator of beta-cell apoptosis suggest an increased apoptosis rate in hepatocyte nuclear factor 1 alpha (HNF1A-MODY) carriers from the third decade of life onward. BMC Endocr Disord (2012) 0.80
Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure. J Diabetes Investig (2010) 0.80
Assessment of re-aggregated human pancreatic islets for secondary drug screening. Br J Pharmacol (2014) 0.80
Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance. J Diabetes Investig (2011) 0.80
Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Ther (2017) 0.78
Gastrointestinal metabolic surgery for the treatment of type 2 diabetes mellitus. World J Gastroenterol (2014) 0.78
Differential stimulation of insulin secretion by GLP-1 and Kisspeptin-10. PLoS One (2014) 0.78
Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes switched from glinides. J Diabetes Investig (2013) 0.78
Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J Diabetes (2014) 0.78
Pancreatic β-Cell Mass as a Pharmacologic Target in Diabetes. Mcgill J Med (2009) 0.78
Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats. Exp Biol Med (Maywood) (2015) 0.78
Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering. Hippokratia (2012) 0.77
An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. Mediators Inflamm (2013) 0.77
American College of Endocrinology Pre-Diabetes Consensus Conference: part three. Diabetes Care (2008) 0.77
Longer-Term Physiological and Metabolic Effects of Gastric Bypass Surgery. Curr Diab Rep (2016) 0.77
Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets. Diabetes Metab Syndr Obes (2015) 0.76
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes. J Clin Med (2014) 0.76
Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models. Acta Pharmacol Sin (2012) 0.76
From Beta cell replacement to beta cell regeneration: implications for antidiabetic therapy. J Diabetes Sci Technol (2014) 0.76
Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers. Drugs R D (2014) 0.76
Synergy Between Gαz Deficiency and GLP-1 Analog Treatment in Preserving Functional β-Cell Mass in Experimental Diabetes. Mol Endocrinol (2016) 0.76
Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs. Pharmaceuticals (Basel) (2010) 0.76
Gastrointestinal dopamine as an anti-incretin and its possible role in bypass surgery as therapy for type 2 diabetes with associated obesity. Minerva Endocrinol (2015) 0.75
GLP-1(28-36)amide, a Long Ignored Peptide Revisited. Open Biochem J (2014) 0.75
Incretins and the intensivist: what are they and what does an intensivist need to know about them? Crit Care (2014) 0.75
Pharmacological Modulators of Endoplasmic Reticulum Stress in Metabolic Diseases. Int J Mol Sci (2016) 0.75
Chronic exposure to GLP-1 increases GLP-1 synthesis and release in a pancreatic alpha cell line (α-TC1): evidence of a direct effect of GLP-1 on pancreatic alpha cells. PLoS One (2014) 0.75
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet (2011) 5.70
Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res (2011) 4.84
Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem (2005) 4.40
Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab (2003) 4.05
Diabetes and cancer: a consensus report. CA Cancer J Clin (2010) 3.95
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA (2003) 3.33
Mutations in the gene encoding filamin B disrupt vertebral segmentation, joint formation and skeletogenesis. Nat Genet (2004) 2.94
Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res (2003) 2.68
Insulin secretion in type 1 diabetes. Diabetes (2004) 2.59
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology (2002) 2.13
Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care (2009) 2.02
Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes (2007) 2.01
Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes (2006) 1.96
Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway. Endocrinology (2002) 1.95
Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care (2002) 1.92
Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care (2003) 1.86
Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes (2014) 1.81
Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care (2013) 1.81
IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci U S A (2007) 1.77
Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet (2002) 1.76
FunciSNP: an R/bioconductor tool integrating functional non-coding data sets with genetic association studies to identify candidate regulatory SNPs. Nucleic Acids Res (2012) 1.71
Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. J Exp Med (2009) 1.68
Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology (2003) 1.68
Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. J Exp Med (2007) 1.67
Mitochondrial myopathy and sideroblastic anemia (MLASA): missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation. J Biol Chem (2005) 1.52
Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest (2004) 1.50
Transforming growth factor-beta/Smad3 signaling regulates insulin gene transcription and pancreatic islet beta-cell function. J Biol Chem (2009) 1.49
Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant (2002) 1.48
Gene expression profiling of cultured human islet preparations. Diabetes Technol Ther (2004) 1.42
Influence of excess fat on cardiac morphology and function: study in uncomplicated obesity. Obes Res (2002) 1.39
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Ex vivo culture with human brain endothelial cells increases the SCID-repopulating capacity of adult human bone marrow. Blood (2002) 1.33
GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev (2003) 1.33
Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ Res (2009) 1.31
Association of the human adiponectin gene and insulin resistance. Eur J Hum Genet (2004) 1.28
Pancreas duodenum homeobox-1 regulates pancreas development during embryogenesis and islet cell function in adulthood. Eur J Endocrinol (2002) 1.28
Fatty acid translocase (FAT/CD36) is localized on insulin-containing granules in human pancreatic beta-cells and mediates fatty acid effects on insulin secretion. Diabetes (2005) 1.24
Pancreatic islet transplantation. PLoS Med (2004) 1.21
Assessment of pancreatic islet mass after islet transplantation using in vivo bioluminescence imaging. Transplantation (2005) 1.15
Transcriptional analysis of intracytoplasmically stained, FACS-purified cells by high-throughput, quantitative nuclease protection. Nat Biotechnol (2009) 1.13
The +276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients. Diabetes Care (2004) 1.12
Novel protective properties of IGFBP-3 result in enhanced pericyte ensheathment, reduced microglial activation, increased microglial apoptosis, and neuronal protection after ischemic retinal injury. Am J Pathol (2011) 1.12
Novel pathway of adipogenesis through cross-talk between adipose tissue macrophages, adipose stem cells and adipocytes: evidence of cell plasticity. PLoS One (2011) 1.12
Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J Clin Endocrinol Metab (2003) 1.12
Blood glucose levels regulate pancreatic beta-cell proliferation during experimentally-induced and spontaneous autoimmune diabetes in mice. PLoS One (2009) 1.11
The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J (2011) 1.11
Genome-wide Runx2 occupancy in prostate cancer cells suggests a role in regulating secretion. Nucleic Acids Res (2011) 1.11
Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol (2003) 1.10
Comprehensive functional annotation of seventy-one breast cancer risk Loci. PLoS One (2013) 1.10
Increased insulin translation from an insulin splice-variant overexpressed in diabetes, obesity, and insulin resistance. Mol Endocrinol (2004) 1.10
Dynamic changes in pancreatic endocrine cell abundance, distribution, and function in antigen-induced and spontaneous autoimmune diabetes. Diabetes (2009) 1.10
Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes. J Immunol (2003) 1.09
Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions. PLoS Genet (2012) 1.07
Uncoupling intensive insulin therapy from weight gain and hypoglycemia in type 1 diabetes. Diabetes Technol Ther (2011) 1.07
Chlamydia heat shock protein 60 induces trophoblast apoptosis through TLR4. J Immunol (2006) 1.06
Regulation of adult hematopoietic stem cells fate for enhanced tissue-specific repair. Mol Ther (2009) 1.05
Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis (2008) 1.05
A proinsulin gene splice variant with increased translation efficiency is expressed in human pancreatic islets. Endocrinology (2002) 1.05
PEDF regulates vascular permeability by a γ-secretase-mediated pathway. PLoS One (2011) 1.05
Oxidative stress in diabetes-induced endothelial dysfunction involvement of nitric oxide and protein kinase C. Free Radic Biol Med (2003) 1.03
Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J (2004) 1.03
Human resistin gene, obesity, and type 2 diabetes: mutation analysis and population study. Diabetes (2002) 1.02
An early requirement for maternal FoxH1 during zebrafish gastrulation. Dev Biol (2007) 1.02
Bone marrow-CNS connections: implications in the pathogenesis of diabetic retinopathy. Prog Retin Eye Res (2012) 1.01
The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity. Eur J Hum Genet (2004) 1.00
Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability. PLoS One (2011) 1.00
Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase). Invest Ophthalmol Vis Sci (2011) 1.00
Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations. PLoS One (2009) 0.99
Transcriptional profiling of endogenous germ layer precursor cells identifies dusp4 as an essential gene in zebrafish endoderm specification. Proc Natl Acad Sci U S A (2008) 0.98
Is a long-term aerobic plus resistance training program feasible for and effective on metabolic profiles in type 2 diabetic patients? Diabetes Care (2004) 0.98
T cell-directed therapies: lessons learned and future prospects. Nat Immunol (2007) 0.98
Differences in the management of type 1 diabetes among adults under excellent control compared with those under poor control in the T1D Exchange Clinic Registry. Diabetes Care (2013) 0.97
Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun (2003) 0.97
Adenovirus-mediated XIAP gene transfer reverses the negative effects of immunosuppressive drugs on insulin secretion and cell viability of isolated human islets. Diabetes (2005) 0.97
CT60 single nucleotide polymorphisms of the cytotoxic T-lymphocyte-associated antigen-4 gene region is associated with Graves' disease in an Italian population. Thyroid (2005) 0.97